| 2.53 -0.06 (-2.32%) | 06-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.62 |
1-year : | 4.23 |
| Resists | First : | 3.09 |
Second : | 3.62 |
| Pivot price | 2.53 |
|||
| Supports | First : | 2.25 |
Second : | 1.87 |
| MAs | MA(5) : | 2.68  |
MA(20) : | 2.63 |
| MA(100) : | 2.29 |
MA(250) : | 1.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55 |
D(3) : | 57.5 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 4 | Low : | 0.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BYSI ] has closed above bottom band by 48.6%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.7 - 2.72 | 2.72 - 2.73 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.5 - 2.53 | 2.53 - 2.55 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Fri, 21 Jun 2024
BeyondSpring (NASDAQ:BYSI) Shares Down 8.8% - MarketBeat
Wed, 12 Jun 2024
BeyondSpring Inc. Announces Share Issuance - TipRanks
Wed, 22 May 2024
BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year - Yahoo Finance
Mon, 29 Apr 2024
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results - Yahoo Finance
Mon, 25 Mar 2024
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 ... - Yahoo Finance
Tue, 05 Mar 2024
Do Traders Think Beyondspring Inc (BYSI) Can Keep Climbing Tuesday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2.385e+007 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 2,390 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.281e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 99.3 % |
| Return on Equity (ttm) | -40.7 % |
| Qtrly Rev. Growth | 1.75e+006 % |
| Gross Profit (p.s.) | 72.68 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.51 |
| Dividend | 0 |
| Forward Dividend | 2.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|